NEWSLETTERS - The Huntington's Disease News
By AICH - Roma Onlus
View this email in your browser
Newsletters 16 Nov.  2016
Huntington's disease news
Ott. 20,  2016
Teva Announces FDA Acceptance of Resubmitted New Drug Application for SD-809 for Treatment of Chorea Associated with Huntington Disease

Today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application (NDA) for SD-809 (deutetrabenazine) for the treatment of chorea associated with Huntington disease (HD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 3, 2017.


Nov. 1  2016

Important advances in next generation genome editing tools for Huntington’s Disease

Recent days have seen a slew of news emerging regarding the use of something called genome editing as a potential therapy for genetic diseases like Huntington’s Disease. These approaches, which include exotic sounding tools like zinc finger nucleases and CRISPR/Cas9, differ from more traditional ways reducing the impact of the HD mutation on cells. What’s new in this exciting area of research?


Nov 1, 2016
The 2016 plenary meeting followed EHDN tradition in bringing together scientists and clinicians from diverse specialities with people affected by HD and their families and carers. This year there was one important innovation, however: we asked presenters to preface their talks with a few words that explained the significance of their work in plain language. 
Read More
Nov 3, 2016
Critical Path Institute (C-Path) and CHDI Foundation, Inc., are collaborating to set up a broad-based consortium that will more clearly define regulatory pathways leading to the approval of Huntington’s disease (HD) therapeutics.
Read More
Nov 7, 2016
Researchers at Stanford University School of Medicine have identified several new biological markers to measure the progression of the inherited neurodegenerative disorder Huntington’s disease (HD). Their findings, which will be published online November 7 ahead of issue in The Journal of Experimental Medicine, could benefit clinical trials that test new treatments for the disease.
Read More
Nov 8, 2016
Huntington’s disease is a neurodegenerative disease that is presently incurable. Scientists around the world are researching its causes and molecular processes in the attempt to find a treatment.
Read More
Nov 11, 2016
Rice University scientists have uncovered new details about how a repeating nucleotidesequence in the gene for a mutant protein may trigger Huntington’s and other neurological diseases.
Read More
Copyright © 2016 aichroma, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

Email Marketing Powered by Mailchimp